Introduction
Core-binding factors (CBFs) are heterodimeric transcription factors consisting of a DNA-binding subunit (CBF␣) and a non-DNAbinding CBF␤ subunit. [1] [2] [3] Three genes in mammals encode CBF␣ subunits (Runx1, Runx2, Runx3, formerly known as Cbfa2, Cbfa1, and Cbfa3, respectively), whereas the CBF␤ subunit is encoded by one gene, Cbfb. [1] [2] [3] [4] [5] [6] [7] [8] CBF␤ heterodimerizes with all 3 CBF␣ subunits in vitro, but the functional significance of this interaction has been shown only for Runx1. Homozygous disruption of either the gene encoding Runx1 or CBF␤ caused identical developmental defects, indicating that both subunits are essential for the Runx1-CBF␤ heterodimer to function in vivo. [9] [10] [11] [12] [13] The CBFs function in multiple developmental pathways in mammals and invertebrates. The Drosophila runt gene, which encodes a CBF␣ subunit, is involved in sex determination, segmentation, and neurogenesis. [14] [15] [16] [17] The related gene lozenge plays a role in developmental pathways involving the eye, antenna, and tarsal claws, and in the formation of crystal cells, a lineage of blood cells in the fly. [18] [19] [20] The mammalian Runx2 gene is required for bone formation, 21, 22 and both Runx1 and Cbfb are required for definitive hematopoiesis. [9] [10] [11] [12] [13] Definitive hematopoiesis is the second wave of hematopoiesis in the developing vertebrate embryo and produces hematopoietic cells of the lymphoid, myeloid, and enucleated (definitive) erythroid lineages. Definitive hematopoiesis is preceded by primitive erythropoiesis, which occurs in the yolk sac and produces a transient population of nucleated primitive erythrocytes and macrophages. Progenitors and stem cells that give rise to the definitive hematopoietic lineages emerge in the yolk sac, the para-aortic splanchnopleure, the vitelline and umbilical arteries, and in the aorta/genital ridge/mesonephros (AGM) region in mammalian embryos. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Homozygous disruption of Runx1 or Cbfb does not appear to significantly impair the first stage of primitive erythropoiesis in the yolk sac, but blocks the second wave of definitive hematopoiesis. [9] [10] [11] [12] [13] RUNX1 (AML1) and CBFB are frequent targets of chromosomal translocations in human leukemias. 36 RUNX1 is disrupted by the t(8;21)(q22;q22) and t(12;21)(p13;q22) in acute myeloid and lymphocytic leukemias, 4, 37, 38 and by the t(3;21)(q26;q22) and t(16;21)(q24;q22) in therapy-related leukemias and myelodysplasias. 39, 40 CBFB is disrupted in acute myeloid leukemias by inv(16)(p13;q22), t (16;16) , and del(16)(q22). 6 The translocations generate chimeric proteins that contain all or part of Runx1 or CBF␤ fused to sequences encoded in the other chromosomal segment involved in the translocation. For example, the inv 16 that disrupts CBFB results in a chimeric protein that contains most of the CBF␤ protein fused to the C-terminal ␣-helical rod domain from a smooth muscle myosin heavy chain (SMMHC) encoded by the MYH11 gene. 6 Genetic experiments in mice demonstrated that the CBF␤-SMMHC protein transdominantly inhibits wild-type Runx1:CBF␤ function in vivo, in that mice heterozygous for a "knocked-in" CBFB-MYH11 allele die at midgestation from essentially the same defect exhibited by mice deficient for Runx1 or Cbfb. 41 Expression of a CBFB-MYH11 transgene in myeloid lineage cells impaired neutrophilic differentiation and this effect was enhanced by an activated N-ras oncogene. 42 The CBF␤-SMMHC protein is thought to transdominantly inhibit Runx1:CBF␤ function by heterodimerizing with RUNX1 and sequestering it on actin filaments in the cytoplasm, 43, 44 or by functioning as a dedicated transcriptional repressor in the nucleus. 45 A number of studies have demonstrated the utility of differentiating mouse embryonic stem (ES) cells in vitro to study hematopoiesis, 46 and showed that ES cells deficient in proteins critical for hematopoiesis in the embryo often show similar hematopoietic impairments in vitro. For example, GATA-1-deficient ES cells fail to develop primitive erythroid precursors in vitro, and definitive erythropoiesis is blocked at the proerythroblast stage of development. 47 Ectopic expression of GATA-1 transgenes in an immature erythroid cell line derived from GATA-1-deficient ES cells restored terminal erythroid differentiation in vitro. 48 SCL-deficient ES cells fail to generate either primitive or definitive hematopoietic cells of all lineages, and this defect could be rescued by ectopic expression of the Scl transgene. 49, 50 ES cells homozygous for deletion of PU.1 produce no detectable myeloid cells in vitro, but expression of a PU.1 transgene restored myelopoiesis. 51, 52 Runx1-deficient ES cells cannot produce definitive hematopoietic progenitors, but a Runx1 transgene knocked into the Runx1 locus rescued definitive hematopoiesis. 53 Here we demonstrate that Cbfbdeficient ES cells undergo primitive erythropoiesis in vitro, but are impaired in their ability to undergo definitive hematopoiesis. Ectopic expression of Cbfb transgenes from the murine stem cell virus (MSCV) restores definitive hematopoiesis of CBF␤-deficient ES cells. We demonstrate that the heterodimerization domain in CBF␤ is sufficient for its function in this assay. In contrast, the CBF␤-SMMHC fusion protein is unable to rescue definitive hematopoiesis by CBF␤-deficient ES cells, and thus cannot provide CBF␤ function in vivo. We also show that the CBF␤-SMMHC protein does not completely impair definitive hematopoiesis in cells containing one copy of the Cbfb-MYH11 allele and one wild-type Cbfb allele, indicating that Runx1-CBF␤ function is not completely inhibited by the CBF␤-SMMHC protein.
Materials and methods

Retroviral transfer of Cbfb complementary DNAs to Cbfb ؊/؊ ES cells
Runx1 Ϫ/Ϫ , Cbfb ϩ/Ϫ , Cbfb Ϫ/Ϫ , and Cbfb Cbfb-MYH11/ϩ ES cells were derived previously. 10, 11, 41 Murine Cbfb complementary DNAs (cDNAs) were subcloned into a murine stem cell viral vector harboring a puromycin-Nacetyltransferase gene (MSCVpac) 54 (subcloning details will be provided on request). Transfection of the packaging cell line and transduction of ϩ/ϩ, Cbfb ϩ/Ϫ , and Cbfb Ϫ/Ϫ ES cells were performed as described by Pear and coworkers. 55 Briefly, BOSC23 cells were transiently transfected by the CaCl 2 precipitate method in the presence of 25 mM chloroquine. Retroviral supernatants (3 mL) were harvested 48 hours later, passed through 0.2 m filters, and added directly to subconfluent ES cell cultures. Polybrene (4 g/mL; hexadimethrine bromide; Sigma, St Louis, MO) was added and cultures were incubated at 37°C for 3 hours. ES cell culture medium (described below) was added (7 mL) and the cultures were continued with daily changes of medium. After 48 hours, transduced ES cells were selected with 2 mg/mL puromycin and maintained in the presence of puromycin until cells in control cultures were no longer alive. Resistant cells were expanded and tested for transgene expression by Western blotting. Thereafter, cells were grown either in the absence or presence of puromycin, but no significant difference was observed in either protein expression or hematopoietic differentiation under the 2 conditions.
Western blot analyses
The ES cell lysates were collected in IP buffer (150 mM NaCl, 50 mM Tris [pH 8 .0], 1% Nonidet P-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate [SDS], 0.2 mM EDTA, 2.0 mM EGTA) plus protease inhibitors (1 mg/mL pepstatin A, 1 mM Pefablock, 2 mg/mL leupeptin, 2 mg/mL aprotinin). Lysates were boiled in SDS loading buffer, resolved on 13% SDS-polyacrylamide gels, and proteins were transferred to nitrocellulose. CBF␤ proteins were detected with mouse monoclonal antibody ␤141.2 and enhanced chemiluminescence (ECL) reagents (Amersham, Piscataway, NJ).
Cell culture and in vitro differentiation
The ES cells were maintained on gelatinized flasks in Dulbecco modified Eagle medium (DMEM) with 15% fetal calf serum (FCS; Hyclone, Logan, UT), 1.5 ϫ 10 Ϫ4 M monothioglycerol (MTG), 50 U/mL penicillin G, 50 g/mL streptomycin, and 1000 U/mL leukemia inhibitory factor (LIF) (Gibco/BRL, Rockville, MD). In vitro hematopoietic differentiation was performed as described. Two days before the initiation of differentiation, cells were transferred to Iscoves modified Dulbecco medium (IMDM) containing the above components. ES cells were trypsinized into a single-cell suspension and plated into primary differentiation media containing 1% methylcellulose (Fluka, Ronkonkoma, NY) in IMDM supplemented with 15% FCS, 2 mM L-glutamine, 1.5 ϫ 10 Ϫ4 M MTG, 50 g/mL ascorbic acid, 200 g/mL iron-saturated transferrin, interleukin 3 (IL-3) (20 ng/mL), IL-11 (10 ng/mL), and 5 ng/mL vascular endothelial growth factor (VEGF). After 6 or 10 days in culture, embryoid bodies (EBs) were disaggregated and replated into secondary methylcellulose cultures containing 10% plasma-derived serum (Antech, Tyler, TX), 5% protein-free hybridoma medium (PFHM2, Gibco/BRL) and cytokines. Primitive erythroid colony (EryP) precursors were enumerated by replating cells into medium containing erythropoietin (Epo; 2 U/mL). Epo (2 U/mL), granulocyte colony-stimulating factor (G-CSF; 2 ng/mL), granulocyte-macrophage CSF (GM-CSF; 5 ng/mL), macrophage CSF (M-CSF; 5 ng/mL), stem cell factor (SCF; 50 ng/mL), IL-1 (5 ng/mL), IL-3 (20 ng/mL), IL-6 (5 ng/mL), IL-11 (10 ng/mL), VEGF (5 ng/mL), and LIF (1 ng/mL) were added to secondary cultures to support differentiation of EryP, definitive erythroid (EryD), myeloid, and mixed lineage colonies. All cytokines and growth factors were purchased from R & D Systems (Minneapolis, MN). After 7 days of secondary culture, colonies were counted on an inverted light microscope. Cells were harvested, pelleted, washed once in serum-free IMDM, and counted before the preparation of cytospins. Slides were stained with Wright-Giemsa. Differential counts were performed by 2 individuals without knowledge of specimen identifications.
Two hematopoietic cell lines derived from ES cells expressing the CBF␤-SMMHC protein were generated by harvesting all colonies from a secondary differentiation plate, washing once with serum-free IMDM, then transferring cells to liquid cultures of RPMI 1640 media supplemented with 10% FCS, 2 mM L-glutamine, 50 U/mL penicillin G, 50 g/mL streptomycin, 10 ng/mL IL-6, 10 ng/mL SCF, and 2 ng/mL IL-3.
Globin analysis
Globin gene expression patterns of colonies from secondary differentiation cultures were analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR). RNA was isolated using GlassMAX RNA Microisolation Spin Cartridges (Gibco/BRL) and following manufacturer's instructions. The Qiagen OneStep RT-PCR kit (Qiagen, Valencia, CA) was used for both reverse transcription and PCR amplification using previously published primers. 56 
FACS analysis
Cell surface antigens were detected by standard immunofluorescence assays using phycoerythrin (PE)-conjugated monoclonal antibodies to CD116 (Mac-1), CD117 (c-kit), CD44, CD45R (B220), and CD31 (Pecam-1). PE-conjugated streptavidin was used to detect biotinylated antibody to CD34. Appropriate isotype controls were included in all experiments. Reagents for flow cytometry were obtained from Pharmingen (San Diego, CA). Fluorescence was analyzed on a FACScan (Becton Dickinson, San Jose, CA).
Results
Definitive hematopoiesis is impaired in Runx1 and CBF␤-deficient ES cells
Keller and coworkers demonstrated that ES cells cultured under specific conditions generate differentiated hematopoietic cells in vitro. 56 Both the kinetics of precursor development and the responsiveness to growth factors are similar to those found in yolk sac and fetal liver, paralleling hematopoietic development that occurs in the embryo. Large numbers of primitive erythroid precursors emerge first, peaking at day 7 of primary culture, followed by precursors for definitive erythroid, myeloid, and mixed erythroid/myeloid lineage colonies (peaking at days 8-10), and finally mast cell precursors (day 10). We cultured wild-type, Runx1 Ϫ/Ϫ , and Cbfb Ϫ/Ϫ ES cells in vitro to generate EBs, as schematically illustrated in Figure 1A , disaggregated the EBs 6 and 10 days after the establishment of the primary culture, and replated the cells in the presence of hematopoietic growth factors. Cells from day 6 EBs were cultured with Epo to enumerate primitive erythroid precursors, and cells from day 10 EBs were cultured in a combination of hematopoietic growth factors that support the differentiation of both primitive and definitive hematopoietic lineages. Day 6 EBs from wild-type, Runx1 Ϫ/Ϫ , or Cbfb Ϫ/Ϫ ES cells contained large numbers of progenitors for primitive erythroid colonies ( Figure 1C ). Primitive erythroid colonies are smaller and brighter red and composed of larger cells than definitive erythroid colonies. Primitive erythroid progenitors were still present in secondary cultures of day 10 EBs from all 3 ES cell lines; however, as expected, their numbers dropped markedly. 56 Only day 10 EBs from wild-type ES cells contained progenitors for all lineages of definitive colonies. Day 10 EBs from Runx1 Ϫ/Ϫ ES cells contained only primitive erythroid progenitors, whereas day 10 EBs from Cbfb Ϫ/Ϫ ES cells contained primitive erythroid progenitors and reduced numbers of progenitors for myeloid colonies ( Figure 1B) . Thus, the hematopoietic defect in ES cell cultures mimics that seen in Runx1-and CBF␤-deficient mice, in that definitive hematopoiesis is blocked while primitive erythropoiesis is spared. The small number of myeloid progenitors in Cbfb Ϫ/Ϫ ES cells also reflects data obtained in mice, where we observed the number of definitive hematopoietic progenitors was severely, but not completely, depressed in the fetal liver and yolk sac. 11
Ectopic expression of Cbfb transgenes rescues definitive hematopoiesis by CBF␤-deficient ES cells
Four distinct cDNAs representing alternatively spliced isoforms of CBF␤ have been isolated 2,3 ( Figure 2A ). Two isoforms, CBF␤(p22) and CBF␤(p21.5), encode CBF␤ proteins containing 187 and 182 amino acids, respectively, that heterodimerize efficiently with CBF␣ subunits in vitro. 2, 3 The CBF␤(p17.6) isoform lacks amino acids encoded in exon 3 and fails to heterodimerize with CBF␣ in vitro. 3 CBF␤(p18) lacks amino acids encoded in exon 5, including the last 2 amino acids (aa 134-135) in the domain that mediates heterodimerization with CBF␣. 57 The Cbfb Ϫ/Ϫ ES cells used in the in vitro differentiation assay contain a deletion in exon 5 of the Cbfb gene. 11 RT-PCR products encoding the CBF␤(p18) isoform were amplified from embryos produced from the same Cbfb Ϫ/Ϫ ES cells; however, a noticeable decrease in Cbfb messenger RNA level was observed compared to wild-type embryos. 11 Western blotting with both embryos and ES cells showed that levels of the truncated CBF␤(p18) protein were greatly reduced compared with those of the endogenous CBF␤(p22) and CBF␤(p21.5) proteins. 11 Heterodimerization of CBF␤(p18) with CBF␣ on DNA in vitro was shown to be relatively weak. 11, 57 Specifically, CBF␤(p18) dissociates more readily from the CBF␣-DNA complex than does CBF␤(p22) or CBF␤(p21.5) during the process of electrophoresis through polyacrylamide gels in electrophoretic mobility shift assays.
We introduced transgenes encoding all 4 CBF␤ isoforms into Cbfb Ϫ/Ϫ ES cells using the MSCV retroviral vector. 54 Pools of drug-resistant ES cells were isolated and screened for CBF␤ expression by Western blot ( Figure 2B ). Ectopically expressed CBF␤(p22) and CBF␤(p21.5) comigrate with endogenous CBF␤ and accumulate at levels similar to that of the endogenous protein(s) in cells. Ectopically expressed CBF␤(p18) migrates faster than endogenous CBF␤ through SDS-polyacrylamide gels. The steady-state level of ectopically expressed CBF␤(p18) ( Figure  2B , lanes 7-8) was similar to that of the endogenous CBF␤(p22) and/or CBF␤(p21.5) protein in wild-type ES cells ( Figure 2B , lane 1), but much greater than that of endogenous CBF␤(p18) in either Cbfb ϩ/ϩ or Cbfb Ϫ/Ϫ ES cells ( Figure 2B, lanes 1-2) . Ectopically expressed CBF␤(p17.6), as well as endogenous CBF␤(p17.6), were not detectable by Western blot.
Ectopic expression of CBF␤(p22) and CBF␤(p21.5) in Cbfb Ϫ/Ϫ ES cells rescued definitive hematopoiesis, indicating that both of these CBF␤ isoforms are functional in vivo ( Figure 2C-E) . Ectopic expression of CBF␤(p18) also restored definitive hematopoiesis ( Figure 2E ). Although the Cbfb Ϫ/Ϫ ES cells may produce the CBF␤(p18) isoform from the mutated Cbfb locus, 11 its concentration in Cbfb Ϫ/Ϫ cells and embryos was apparently insufficient for in vivo function. However, the residual CBF␤(p18) activity in Cbfb Ϫ/Ϫ cells may account for the small numbers of definitive hematopoietic progenitors found in both ES cell cultures and mouse embryos. 11 The CBF␤(p17.6) failed to rescue definitive hematopoiesis (not shown). This result cannot be interpreted as an intrinsic failure of CBF␤(p17.6) to rescue because the protein was not detectable.
The heterodimerization domain for the CBF␣ proteins is contained within the N-terminal 135 amino acids of CBF␤(p22) and CBF␤(p21.5). 57 We previously showed that an amino acid 1 to 141 fragment of CBF␤, referred to as CBF␤(141), binds to a Runx1-DNA complex with a K d equivalent to that of full-length CBF␤(p22). 58 CBF␤(141) also assumes a folded structure indistinguishable from that which it assumes in the context of the full-length protein. 58 Ectopic expression of CBF␤(141) restores definitive hematopoiesis by Cbfb Ϫ/Ϫ ES cells ( Figure 2E ). The presence of definitive erythroid colonies was confirmed by RT-PCR analysis of ␤-globin expression ( Figure 2D ). Primitive erythroid cells express both embryonic (␤H1) and adult type (␤ major) ␤-globin, whereas definitive erythroid cells express only the ␤ major gene. Individual definitive erythroid colonies isolated from secondary cultures of Cbfb Ϫ/Ϫ ES cells expressing CBF␤(141) transcribed the ␤ major, but not the ␤H1 gene ( Figure 2D, lanes  7-8) . Therefore, the heterodimerization domain of CBF␤, which is common to both the CBF␤(p21.5) and CBF␤(p22) isoforms, is sufficient for CBF␤ function in hematopoiesis in this assay system.
One limitation of the rescue assay is that numbers of definitive colonies produced from both Cbfb ϩ/ϩ ES cells and Cbfb Ϫ/Ϫ ES cells expressing various transgenes varied from 5-to 20-fold between experiments, making quantitative comparisons of the ability to rescue difficult. Although the rescue assay is not quantitative, under no circumstances did we detect progenitors for definitive erythroid or mixed erythroid/myeloid lineage colonies in EBs derived from Cbfb Ϫ/Ϫ ES cells. Therefore, we scored the appearance of definitive erythroid and mixed erythroid/myeloid lineage progenitors as rescue, and the absence of such progenitors as failure to rescue.
CBF␤-SMMHC fails to rescue hematopoiesis by Cbfb ؊/؊ ES cells
The CBF␤-SMMHC fusion protein generated as a result of the inv(16) was shown in mouse "knock-in" studies to transdominantly inhibit Runx1-CBF␤ function in vivo. 41 CBF␤-SMMHC contains the N-terminal 165 amino acids of CBF␤, including the intact Runx1 heterodimerization domain, fused to the SMMHC For personal use only. at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From tail. 6 We ectopically expressed a 67-kd isoform of CBF␤-SMMHC in Cbfb ϩ/ϩ , Cbfb ϩ/Ϫ , and Cbfb Ϫ/Ϫ ES cells (Figure 3) . Western blot analysis confirms expression of CBF␤-SMMHC in all 3 cell lines ( Figure 3B ). The CBF␤-SMMHC protein concentration appears to be lower than that of endogenous CBF␤ ( Figure 3B, lanes 2 and 4) , but the transfer efficiency of the 2 proteins may differ, making direct comparisons difficult. Progenitors for definitive erythroid and mixed lineage colonies were present in EBs derived from Cbfb ϩ/ϩ and Cbfb ϩ/Ϫ ES cells expressing the CBF␤-SMMHC transgene ( Figure 3C ), indicating that ectopic expression of the CBF␤-SMMHC protein from the MSCV enhancer cannot significantly impair definitive hematopoiesis in this assay system. We also determined whether ectopic expression of CBF␤-SMMHC fusion proteins could restore definitive hematopoiesis by Cbfb Ϫ/Ϫ ES cells. Expression of either the 67-kd ( Figures 3C and  4C) or the 71-kd ( Figure 4C ) isoforms of CBF␤-SMMHC failed to rescue definitive hematopoiesis. This indicates either that expression levels of these proteins were insufficient to restore CBF␤ function, or that the CBF␤-SMMHC proteins are intrinsically defective in providing CBF␤ function in vivo. However, a truncated form of the CBF␤-SMMHC protein lacking the C-terminal 317 amino acids of the SMMHC tail region, CBF␤-SMMHC ⌬C317 (Figure 4A ), when ectopically expressed at approximately equivalent levels as the full-length CBF␤-SMMHC proteins ( Figure 4B,  lanes 3, 4, and 7) , rescued definitive hematopoiesis of Cbfb Ϫ/Ϫ ES cells ( Figure 4C ). CBF␤-SMMHC ⌬C317 lacks SMMHC sequences that enable it to associate with and sequester CBF␣ subunits on cytoplasmic actin filaments. 44 We therefore conclude that the full-length CBF␤-SMMHC protein is intrinsically deficient in its 
CBF␤-SMMHC impairs myeloid cell differentiation
To address the possibility that the concentration of ectopically expressed CBF␤-SMMHC was not adequate to overcome endogenous wild-type CBF␤ function in this assay, we analyzed the hematopoietic potential of ES cells heterozygous for a Cbfb-MYH11 "knock-in" allele. This allele was generated by replacing a portion of exon 5 from the mouse Cbfb gene with exon 5 sequences from the human CBFB gene, fused to MYH11 sequences. 41 Both the normal CBF␤ proteins and the 71-kd CBF␤-SMMHC fusion protein are expressed from the endogenous Cbfb promoters in the "knock-in" (Cbfb Cbfb-MYH11/ϩ ) ES cells ( Figure 3B, lane 8) . It was previously demonstrated that embryos heterozygous for the Cbfb Cbfb-MYH11 allele die at midgestation and display impaired definitive hematopoiesis, with severely depressed numbers of definitive hematopoietic progenitors in fetal livers and yolk sacs. 41 The ES cells heterozygous for the Cbfb Cbfb-MYH11 allele produced significantly more definitive hematopoietic progenitors than either Cbfb Ϫ/Ϫ or Runx1 Ϫ/Ϫ ES cells in vitro ( Figures 5A and 1B) . The number of definitive progenitors generated by Cbfb Cbfb-MYH11/ϩ ES cells was in fact only modestly reduced, ranging from 0-to 10-fold in independent experiments, relative to progenitor numbers from wild-type ES cells. Thus, the same ratio of CBF␤-SMMHC to CBF␤ sufficient to cause embryonic lethality in mice is insufficient to completely block definitive hematopoiesis by Cbfb Cbfb-MYH11/ϩ ES cells cultured in vitro.
Although the absolute numbers of definitive colonies produced by the Cbfb Cbfb-MYH11/ϩ ES cells were only modestly reduced compared to wild-type ES cells, expression of the CBF␤-SMMHC fusion protein preferentially inhibited the formation of myeloid colonies, relative to primitive and/or definitive erythroid colonies ( Figure 5B ). Cytospins of secondary cultures from wild-type and Cbfb Cbfb-MYH11/ϩ ES cells revealed significantly different ratios of individual cell types ( Figure 5C ). Most of the cells derived from wild-type ES cells were macrophage-like with prominent foamy cytoplasm. Hematopoietic cells from colonies derived from Cbfb Cbfb-MYH11/ϩ ES cells were more heterogeneous. Many more cells showed evidence of erythroid differentiation, including multinucleate forms. There was some maturation to macrophagelike cells. Occasional cells were granulated, suggesting mast cell differentiation. Many precursor cells with higher nuclear cytoplasmic ratios and nucleoli were also present. Enumeration of these various cell types indicated a decrease in the percentage of mature myeloid cells and an increase in the percentage of erythroid and blast-like cells in cultures derived from Cbfb Cbfb-MYH11/ϩ ES cells ( Figure 5C ). Because we observed an increase in the number of primitive erythroid colonies, we believe that the overall increase in erythroid cells is due to an increase in primitive erythroid cells.
Establishment and characterization of a Cbfb Cbfb-MYH11/؉ cell line
Hematopoietic colonies from secondary cultures of Cbfb ϩ/ϩ , Cbfb Ϫ/Ϫ , and Cbfb Cbfb-MYH11/ϩ ES cells were recovered from methylcellulose cultures, disaggregated, and grown in liquid cultures in the presence of IL-3, IL-6, and SCF, following the procedure described by Okuda and coworkers. 59 Two cell lines were independently derived from the Cbfb Cbfb-MYH11/ϩ ES cells. After approximately 25 days in culture, one cell line (KI-1) began to expand, reaching logarithmic growth after 35 days ( Figure 6A ). The second line (KI-2) began to actively proliferate after approximately 75 days in culture. Viable cells persisted in liquid cultures derived from Cbfb ϩ/ϩ and Cbfb Ϫ/Ϫ ES cells for up to 70 days but active proliferation was never observed and the cell numbers declined steadily over the course of the experiment. Growth and survival of all cells was dependent on the presence of hematopoietic growth factors, and rapid cell death was observed in their absence. Morphologically, cells derived from wild-type ES cells displayed mast cell differentiation with prominent purple granules ( Figure  6B ). Precursor cells with sparse granules, larger nuclei, and prominent nucleoli as well as a few nongranulated precursors were observed. The KI-1 cell line derived from Cbfb Cbfb-MYH11/ϩ ES cells showed similar morphology with most cells displaying some maturation toward mast cells, but occasional large foamy macrophages were also present. The morphology of the KI-2 cells was very distinct from that of either the KI-1 cell line or Cbfb ϩ/ϩ cells. Most KI-2 cells were fairly undifferentiated with prominent nucleoli and large nuclear cytoplasmic ratios. Very few cells possessed granules and several had vacuoles ( Figure 6B ). Both KI-1 and KI-2 cells continued to express the CBF␤-SMMHC protein ( Figure 6C ).
Flow cytometric analysis using a panel of monoclonal antibodies directed against hematopoietic cell surface antigens was used to further characterize the Cbfb Cbfb-MYH11/ϩ KI-1 and KI-2 cell lines ( Figures 6D and E, respectively) . Both cell lines were uniformly positive for high levels of CD44. CD44 is the receptor for Using this assay, we show that 2 CBF␤ isoforms previously shown to form stable heterodimers with CBF␣ in vitro, CBF␤(p22) and CBF␤(p21.5), 2, 3 are both capable of providing CBF␤ function in vivo. A third CBF␤ isoform, CBF␤(p18), which forms an unstable complex with CBF␣ and DNA in vitro, 11,57 also restores definitive hematopoiesis by Cbfb Ϫ/Ϫ ES cells. In addition, we demonstrate that the heterodimerization domain of CBF␤, which mediates its interaction with the CBF␣ Runt domain, is sufficient for its in vivo function with Runx1 in this assay. Kanno and colleagues also showed that the CBF␤ heterodimerization domain can support transactivation by Runx1, using a transient expression and reporter gene assay in Jurkat T cells. 43 We both confirm and extend their analyses by demonstrating the heterodimerization domain of CBF␤ is sufficient to carry out a developmental program that requires CBF␤.
The ability of CBF␤(p18) to rescue hematopoiesis was somewhat unexpected, given that CBF␤(p18) is synthesized from the endogenous mutated Cbfb allele in Cbfb Ϫ/Ϫ ES cells. 11 CBF␤(p18) lacks exon 5-encoded sequences, including 2 amino acids (aa 134-135) at the C-terminus of the heterodimerization domain defined by Kagoshima and coworkers. 57 Amino acids 134 to 135 reside in the middle of an ␣ helix spanning amino acids 129 to 138. 60, 61 Truncation of this ␣ helix in the CBF␤(p18) isoform appears to destabilize the heterodimerization domain to some extent, as evidenced by the instability of ternary Runx1-CBF␤(p18)-DNA complexes in electrophoretic mobility shift assays. 11, 57 However, CBF␤(p18) contains all the amino acids that comprise the interaction surface for the CBF␣ Runt domain, 60 and when present at sufficiently high concentrations can provide CBF␤ function in vivo. Thus, it appears that the hematopoietic block resulting from the mutation we and others introduced into the Cbfb gene 11, 12 was primarily due to insufficient levels of the CBF␤(p18) protein in Cbfb Ϫ/Ϫ ES cells and embryos.
We show that the emergence or differentiation of definitive hematopoietic progenitors from ES cells heterozygous for a "knocked-in" Cbfb Cbfb-MYH11 allele is only modestly impaired in vitro. This was somewhat unexpected given the dramatic phenotype observed in mice heterozygous for the Cbfb Cbfb-MYH11 allele. Cbfb Cbfb-MYH11/ϩ mice die at midgestation with central nervous system (CNS) hemorrhaging and a severe block in fetal liver hematopoiesis. 41 However, more recent results indicate that hematopoietic stem cells (HSCs) hemizygous for the Cbfb Cbfb-MYH11 allele do persist in adult chimeric mice generated with Cbfb Cbfb-MYH11/ϩ ES cells. 62 Cbfb Cbfb-MYH11/ϩ HSCs may have emerged in chimeric mice because of the incomplete repression of normal Runx1-CBF␤ function by the Cbfb Cbfb-MYH11 allele. The Cbfb Cbfb-MYH11/ϩ HSCs were found to give rise to mature erythrocytes efficiently but were unable to differentiate along myeloid and lymphoid lineages. 62 Transgenic mice in which expression of CBF␤-SMMHC was specifically targeted to myeloid cells showed impairment but not a complete block of neutrophil differentiation. 42 The in vivo findings are consistent with ES cell differentiation results reported here and suggest that CBF␤-SMMHC preferentially impairs the differentiation of myeloid lineage cells.
An incomplete block in definitive hematopoiesis was also seen in the t(8;21) knock-in mouse models, in which cDNAs encoding the AML1-ETO fusion protein were introduced into the Runx1 gene. 59, 63 For example, Yergeau and associates demonstrated that although no definitive hematopoietic colonies of any kind could be cultured from yolk sacs derived from 10.5 days post coitus (dpc) Runx1-deficient embryos, macrophage-like colonies differentiated from the yolk sacs of embryos heterozygous for the t(8;21) knock-in allele. 63 More recently and dramatically, Okuda and coworkers reported that in their independently derived t(8;21) knock-in mouse strain, dysplastic progenitors for mixed lineage colonies could be found in the fetal livers of day 11.5 to 13.5 embryos, and that these progenitors had an abnormally high self-renewal capacity. 59 We recently found that the hematopoietic block in Runx1 Ϫ/Ϫ mice occurs during the emergence of definitive hematopoietic progenitors in the embryo 64 (North and colleagues, unpublished results, 2000) . The in vivo data from the t(8;21) knock-in mice generated by Okuda and coworkers suggest that some definitive hematopoietic progenitors escape the early block associated with loss of Runx1 function and emerge, but are unable to complete differentiation into mature myeloid and erythroid cells. 59 The impaired differentiation of myeloid lineage cells may be an important step in leukemogenesis associated with the t(8;21) and inv (16) . Incomplete repression of wild-type Runx1-CBF␤ function by the transdominant negative AML1-ETO and CBFB-MYH11 alleles may allow for the expansion and persistence of a population of myeloid progenitors that then become targets for the secondary mutations required for leukemic transformation.
Continued culture of the colonies derived from Cbfb Cbfb-MYH11/ϩ ES cells resulted in the outgrowth of 2 cell lines, with different morphologic features and cell surface phenotypes. We do not understand the significance of the differences between the 2 cell lines. It is unclear whether the outgrowth from secondary ES cell cultures is directly caused by the presence of the CBF␤-SMMHC protein, and additional experiments are needed to more completely assess the effects of CBF␤-SMMHC on proliferative potential. However, the kinetics of cell outgrowth suggest that the CBF␤-SMMHC protein by itself was insufficient to immortalize primary hematopoietic cells. This is consistent with the demonstration that Cbfb Cbfb-MYH11/ϩ chimeric mice developed leukemias only at a low frequency and after a long latent period. 62 It is interesting to note that although biallelic loss of function mutations in the RUNX1 gene have been found in leukemias, 65 the frequency of chromosomal rearrangements of RUNX1 and CBFB in leukemias is greater. Furthermore, biallelic mutations were observed in M0 leukemias, which are minimally differentiated acute myeloid leukemias, whereas the (8;21) and inv (16) are found in the somewhat more differentiated M2 and M4 acute myeloid leukemia subtypes. The difference in frequency and diagnostic subtypes suggests that the translocations and loss of function mutations involving RUNX1 and CBFB are not equivalent in leukemogenesis. The inability of CBF␤-SMMHC and AML1-ETO to completely inhibit Runx1:CBF␤ activity may be an essential feature of their distinct leukemogenic properties.
We were also able to document an intrinsic inability of CBF␤-SMMHC to provide CBF␤ function in vivo, based on its failure to restore definitive hematopoiesis by Cbfb Ϫ/Ϫ ES cells. This observation could form the basis of an assay for evaluating the biochemical properties of the SMMHC sequences that inhibit its function in vivo, and for testing candidate drugs targeted against the CBF␤-SMMHC protein.
